Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Kenneth M. Faulkner, Karen MacDonald, Ivo Abraham, Abdulaziz Alhossan & Christopher S. Lee. (2021) ‘Real-world’ effectiveness of omalizumab in adults with severe allergic asthma: a meta-analysis. Expert Review of Clinical Immunology 17:1, pages 73-83.
Read now
Read now
Karen M. MacDonald, Abhishek Kavati, Benjamin Ortiz, Abdulaziz Alhossan, Christopher S. Lee & Ivo Abraham. (2019) Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018. Expert Review of Clinical Immunology 15:5, pages 553-569.
Read now
Read now
Stephanie Chen, Sarowar Golam, Julie Myers, Chris Bly, Harry Smolen & Xiao Xu. (2018) Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment. Current Medical Research and Opinion 34:12, pages 2075-2088.
Read now
Read now
Articles from other publishers (23)
Nicola A. Hanania, Robert Niven, Pascal Chanez, Deschildre Antoine, Pascal Pfister, Lorena Garcia Conde & Xavier Jaumont. (2022) Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthma. World Allergy Organization Journal 15:10, pages 100695.
Crossref
Crossref
Serafeim Chrysovalantis Kotoulas, Ioanna Tsiouprou, Eva Fouka, Athanasia Pataka, Despoina Papakosta & Konstantinos Porpodis. (2022) Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma. Journal of Personalized Medicine 12:2, pages 165.
Crossref
Crossref
Jean Bousquet, Marc Humbert, Peter G. Gibson, Konstantinos Kostikas, Xavier Jaumont, Pascal Pfister & Francis Nissen. (2021) Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies. The Journal of Allergy and Clinical Immunology: In Practice 9:7, pages 2702-2714.
Crossref
Crossref
Arjun Mohan, Jon Grace, Anne Mainardi, Geoffrey Chupp & Njira Lugogo. 2020. Difficult To Treat Asthma. Difficult To Treat Asthma
123
153
.
Giorgio Lorenzo Colombo, Sergio Di Matteo, Chiara Martinotti, Martina Oselin, Maria Chiara Valentino, Giacomo Matteo Bruno, Claudia Pitotti & Francesco Menzella. (2019) Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review. Therapeutic Advances in Respiratory Disease 13, pages 175346661984135.
Crossref
Crossref
M.J. Oliveira, M. Vieira, D. Coutinho, I. Ladeira, I. Pascoal, J. Ferreira, J.M. da Silva, A. Carvalho & R. Lima. (2019) Severe asthma in obese patients: Improvement of lung function after treatment with omalizumab. Pulmonology 25:1, pages 15-20.
Crossref
Crossref
Heather Ellen Hoch, William Carl AndersonIIIIII & Stanley James Szefler. 2019. Kendig's Disorders of the Respiratory Tract in Children. Kendig's Disorders of the Respiratory Tract in Children
747
755.e3
.
Paraskevi Katsaounou, Mikaela Odemyr, Otto Spranger, Michael E. Hyland, Claus Kroegel, Lorena Garcia Conde, Robin Gore, Francesco Menzella, Christian Domingo Ribas, Mario Morais-Almeida, Matthias Gasser & Ismail Kasujee. (2018) Still Fighting for Breath: a patient survey of the challenges and impact of severe asthma. ERJ Open Research 4:4, pages 00076-2018.
Crossref
Crossref
Bradley E. Chipps, Leonard B. Bacharier, Judith R. Farrar, Daniel J. Jackson, Kevin R. Murphy, Wanda Phipatanakul, Stanley J. Szefler, W. Gerald Teague & Robert S. Zeiger. (2018) The pediatric asthma yardstick. Annals of Allergy, Asthma & Immunology 120:6, pages 559-579.e11.
Crossref
Crossref
Arzu Yorgancıoğlu, Ferda Öner Erkekol, Dilşad Mungan, Münevver Erdinç, Bilun Gemicioğlu, Zeynep Ferhan Özşeker, Papatya Bayrak Değirmenci , Sibel Naycı, Aykut Çilli, Füsun Erdenen, Cengiz Kırmaz, Dane Ediger, Arzu Didem Yalçın, Suna Büyüköztürk, Sami Öztürk, Mustafa Güleç, Sacide Rana Işık, Ali Fuat Kalyoncu, Özlem Göksel, Ömür Aydın, Yavuz Havlucu, İdilhan Baloğlu Ar & Ahmet Erdoğdu. (2018) Long-Term Omalizumab Treatment: A Multicenter, Real-Life, 5-Year Trial. International Archives of Allergy and Immunology 176:3-4, pages 225-233.
Crossref
Crossref
Mona Al-Ahmad, Nermina Arifhodzic, Jasmina Nurkic, Ahmed Maher, Tito Rodriguez-Bouza, Nasser Al-Ahmed, Ali Sadek & Edin Jusufovic. (2018) "Real-life" Efficacy and Safety Aspects of 4-Year Omalizumab Treatment for Asthma. Medical Principles and Practice 27:3, pages 260-266.
Crossref
Crossref
Laurel Stephenson. (2017) Monoclonal Antibody Therapy for Asthma. Clinical Pulmonary Medicine 24:6, pages 250-257.
Crossref
Crossref
Adel H. Mansur, Sapna Srivastava, Verity Mitchell, Julie Sullivan & Ismail Kasujee. (2017) Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety. Respiratory Medicine 124, pages 36-43.
Crossref
Crossref
M. Caminati, G. Senna, G. Stefanizzi, R. Bellamoli, S. Longhi, F. Chieco-Bianchi, G. Guarnieri, S. Tognella, M. Olivieri, C. Micheletto, G. Festi, E. Bertocco, M. Mazza, A. Rossi & A. Vianello. (2016) Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience. BMC Pulmonary Medicine 16:1.
Crossref
Crossref
Aleksandra Chudzicka, Renata Rożyńska & Adam Wesołowski. (2016) Radykalna poprawa kontroli astmy oskrzelowej po włączeniu do leczenia omalizumabu – opis przypadku. Alergologia Polska - Polish Journal of Allergology 3, pages S10-S13.
Crossref
Crossref
T. Tajiri, H. Matsumoto, Y. Gon, R. Ito, S. Hashimoto, K. Izuhara, M. Suzukawa, K. Ohta, J. Ono, S. Ohta, I. Ito, T. Oguma, H. Inoue, T. Iwata, Y. Kanemitsu, T. Nagasaki, A. Niimi & M. Mishima. (2016)
Utility of serum periostin and free
I
g
E
levels in evaluating responsiveness to omalizumab in patients with severe asthma
. Allergy 71:10, pages 1472-1479.
Crossref
Crossref
Michael Roth, Feng Zhao, Jun Zhong, Didier Lardinois & Michael Tamm. (2015) Serum IgE Induced Airway Smooth Muscle Cell Remodeling Is Independent of Allergens and Is Prevented by Omalizumab. PLOS ONE 10:9, pages e0136549.
Crossref
Crossref
Marco Caminati, Gianenrico Senna, Massimo Guerriero, Anna Rita Dama, Fulvia Chieco-Bianchi, Giorgia Stefanizzi, Marcello Montagni & Erminia Ridolo. (2015) Omalizumab for severe allergic asthma in clinical trials and real-life studies: What we know and what we should address. Pulmonary Pharmacology & Therapeutics 31, pages 28-35.
Crossref
Crossref
Michelle Fox Huffaker & Wanda Phipatanakul. (2015) Pediatric Asthma. Immunology and Allergy Clinics of North America 35:1, pages 129-144.
Crossref
Crossref
Naresh Singh Redhu & Abdelilah S Gounni. (2015) IgE regulates airway smooth muscle phenotype: Future perspectives in allergic asthma. World Journal of Immunology 6:3, pages 126.
Crossref
Crossref
Marco Caminati, Gianenrico Senna, Fulvia Chieco Bianchi, Maria Rita Marchi, Andrea Vianello, Claudio Micheletto, Carlo Pomari, Silvia Tognella, Francesca Savoia, Valentina Mirisola & Andrea Rossi. (2014) Omalizumab management beyond clinical trials: The added value of a network model. Pulmonary Pharmacology & Therapeutics 29:1, pages 74-79.
Crossref
Crossref
Christian Domingo. (2014) Omalizumab for Severe Asthma: Efficacy Beyond the Atopic Patient?. Drugs 74:5, pages 521-533.
Crossref
Crossref
Nathan Hambly & Parameswaran Nair. (2014) Monoclonal antibodies for the treatment of refractory asthma. Current Opinion in Pulmonary Medicine 20:1, pages 87-94.
Crossref
Crossref